Ananda Developments - Appointment of Adviser
Announcement provided by
Ananda Pharma Plc · ANA06/02/2024 07:00
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Appoints Data and Analytics Expert
Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Vitalii Ratushnyi as an adviser to the Company with a focus on data and analytics.
Vitalii is a data, analytics, and quantitative modelling expert. His appointment gives Ananda the analytical capability to better target its research activities by identifying potential current and new disease areas where cannabinoids may be efficacious. His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities. The Company's objective is to provide the evidence required to get cannabis-based medicines available on the NHS.
Ananda CEO Melissa Sturgess commented "We believe our ability to get to grips with large biological and genetic data sets will help us find opportunities for our cannabinoid medicines, guide the design of clinical trials and will be a cornerstone of our success. This work is critical for the rapid development of our clinical trials pipeline and intellectual property estate."
Biography
Vitalii holds a Master of Business Administration from the
To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
For more information please contact:
InvestorHub Engage with us directly at Ananda Developments Investor Hub
|
Sign up at https://investors.anandadevelopments.com/s/a66906
|
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess
Jeremy Sturgess-Smith
|
+44 (0)7463 686 497 ir@anandadevelopments.com |
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Harry Davies-Ball |
+44 (0)20 3470 0470 |
Corporate Broking Abigail Wayne Rob Rees
|
|
Yellow Jersey PR Charles Goodwin Soraya Jackson |
+44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based
medicines for the treatment of complex, chronic inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/Ky0KoP
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.